Loading…
Lobbying Spend
—
Filings
49
Firms Hired
2
Active Period
2016–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2022 · fourth_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $7,000
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2022 · third_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $7,000
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2022 · second_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $9,000
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2022 · first_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $5,250
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2021 · fourth_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $5,250
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2021 · third_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $11,000
Matched citations: S. 2257
Expanding Access to Affordable Prescription Drugs and Medical Devices Act
2021 · second_quarter · Firm: WAXMAN STRATEGIES
Support for non-profit pharmaceutical manufacturers, S. 2257
Client expense: — · Firm income: $9,600
Matched citations: S. 2257
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Client expense: — · Firm income: —
Matched citations: HR 6071
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Client expense: — · Firm income: —
Matched citations: HR 6071
Source: Senate LDA